Patents by Inventor John M. Polo

John M. Polo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9255126
    Abstract: Chimeric alphavirus particles and alphavirus replicon RNAs are provided including methods of making and using same. The alphavirus replicon RNAs comprise deletions in one or more nonstructural proteins. Methods of making, using, and therapeutic preparations containing the chimeric alphavirus particle are disclosed.
    Type: Grant
    Filed: August 10, 2009
    Date of Patent: February 9, 2016
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: John M. Polo, Silvia Perri, Kent Thudium, Zequn Tang
  • Patent number: 8647864
    Abstract: Compositions and methods are provided for Eukaryotic Layered Vector Initiation Systems and Alphavirus replicon particles for introducing heterologous sequences into cells for generating immune responses.
    Type: Grant
    Filed: June 29, 2010
    Date of Patent: February 11, 2014
    Assignee: Novartis AG
    Inventors: John M Polo, Thomas W Dubensky, Jr., Ilya Frolov, Jason P Gardner, Gillis Otten, Susan Barnett, David A Driver
  • Publication number: 20120231526
    Abstract: Methods of production and purification for viruses and virus-derived vectors, including those related to alphaviruses, are disclosed. In one aspect, methods of purification that subject alphavirus replicon particle preparations to one or more steps of chromatographic purification, such as using an ion exchange resin, are provided.
    Type: Application
    Filed: March 27, 2012
    Publication date: September 13, 2012
    Inventors: John M. Polo, Catherine Greer, Maria Calderon-Cacia, Daniel De La Vega, JR., Thomas W. Dubensky, JR.
  • Patent number: 7977091
    Abstract: The present disclosure provides compositions and methods for utilizing recombinant alphavirus vectors. Also disclosed are compositions and methods for making and utilizing eukaryotic layered vector initiation systems.
    Type: Grant
    Filed: August 10, 2009
    Date of Patent: July 12, 2011
    Assignee: Novartis Vaccines & Diagnostics, Inc.
    Inventors: Thomas W. Dubensky, Jr., John M Polo, Carlos E Ibanez, Stephen M. W. Chang, Douglas J Jolly, David A Driver, Barbara A Belli
  • Publication number: 20100330121
    Abstract: Isolated nucleic acid molecules are disclosed, comprising an alphavirus nonstructural protein gene which, when operably incorporated into a recombinant alphavirus particle, eukaryotic layered vector initiation system, or RNA vector replicon, has a reduced level of vector-specific RNA synthesis, as compared to wild-type, and the same or greater level of proteins encoded by RNA transcribed from the viral junction region promoter, as compared to a wild-type recombinant alphavirus particle. Also disclosed are RNA vector replicons, alphavirus vector constructs, and eukaryotic layered vector initiation systems which contain the above-identified nucleic acid molecules.
    Type: Application
    Filed: July 28, 2010
    Publication date: December 30, 2010
    Applicants: NOVARTIS VACCINES AND DIAGNOSTICS, INC., WASHINGTON UNIVERSITY
    Inventors: Thomas W. Dubensky, JR., John M. Polo, Barbara A. Belli, Sergey A. Dryga, Sondra Schlessinger, Ilya Frolov
  • Patent number: 7811812
    Abstract: Isolated nucleic acid molecules are disclosed, comprising an alphavirus nonstructural protein gene which, when operably incorporated into a recombinant alphavirus particle, eukaryotic layered vector initiation system, or RNA vector replicon, has a reduced level of vector-specific RNA synthesis, as compared to wild-type, and the same or greater level of proteins encoded by RNA transcribed from the viral junction region promoter, as compared to a wild-type recombinant alphavirus particle. Also disclosed are RNA vector replicons, alphavirus vector constructs, and eukaryotic layered vector initiation systems which contain the above-identified nucleic acid molecules.
    Type: Grant
    Filed: March 17, 2003
    Date of Patent: October 12, 2010
    Assignee: Novartis Vaccines & Diagnostics, Inc.
    Inventors: Thomas W. Dubensky, Jr., John M. Polo, Barbara A. Belli, Sondra Schlesinger, Sergey A. Drvga, Ilya Frolov
  • Publication number: 20100173412
    Abstract: The present disclosure provides compositions and methods for utilizing recombinant alphavirus vectors.
    Type: Application
    Filed: August 10, 2009
    Publication date: July 8, 2010
    Inventors: Thomas W. Dubensky, JR., John M. Polo, Carlos E. Ibanez, Stephen M.W. Chang, Douglas J. Jolly, David A. Driver, Barbara A. Belli
  • Patent number: 7744900
    Abstract: Expression cassettes are provided comprising a promoter operably linked to a nucleic acid molecule which, when transcribed in vivo, forms double-stranded RNA that induces the production of interferon. Expression cassettes also are provided comprising a promoter operably linked to a ribozyme or antisense nucleic acid molecule which, when transcribed in vivo, forms a ribozyme or antisense RNA molecule that stimulates an immune response. In addition, expression cassettes are provided comprising a promoter operably linked to a ribozyme or antisense nucleic acid molecule which, when transcribed in vivo, stimulates apoptosis. Finally, gene delivery vectors are provided which contain such expression cassettes, host cells containing the gene delivery vectors, and methods of utilizing the expression cassettes, gene delivery vectors, and host cells.
    Type: Grant
    Filed: April 29, 2008
    Date of Patent: June 29, 2010
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Thomas W Dubensky, Jr., John M Polo, Barbara A Belli, Silvia Perri, Timothy C Fong
  • Publication number: 20100055128
    Abstract: Methods of production and purification for viruses and virus-derived vectors, including those related to alphaviruses, are disclosed. in one aspect, methods of purification that subject alphavirus replicon particle preparations to one or more steps of chromatographic purification, such as using an ion exchange resin, are provided. Also disclosed are methods of characterizing alphavirus replicon particles and utilizing these materials for vaccines and gene-based therapeutics.
    Type: Application
    Filed: September 18, 2008
    Publication date: March 4, 2010
    Applicant: Novartis Vaccines and Diagnostics Inc
    Inventors: John M. Polo, Catherine Greer, Maria Calderon-Cacia, Daniel De La Vega, JR., Thomas W. Dubensky, JR.
  • Publication number: 20090305344
    Abstract: Chimeric alphaviruses and alphavirus replicon particles are provided, including methods of making and using same. Specifically, alphavirus particles are provided having nucleic acid molecules derived from one or more alphaviruses and structural proteins (capsid and/or envelope) from at least two or more alphaviruses. Methods of making, using, and therapeutic preparations containing the chimeric alphavirus particle, are disclosed.
    Type: Application
    Filed: February 17, 2009
    Publication date: December 10, 2009
    Applicant: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
    Inventors: John M. POLO, Silvia PERRI, Kent THUDIUM
  • Publication number: 20090304745
    Abstract: Chimeric alphavirus particles and alphavirus replicon RNAs are provided including methods of making and using same. The alphavirus replicon RNAs comprise deletions in one or more nonstructural proteins. Methods of making, using, and therapeutic preparations containing the chimeric alphavirus particle are disclosed.
    Type: Application
    Filed: August 10, 2009
    Publication date: December 10, 2009
    Inventors: John M. Polo, Silvia Perri, Kent Thudium, Zequn Tang
  • Patent number: 7572453
    Abstract: Chimeric alphaviruses and alphavirus replicon particles are provided including methods of making and using same. Specifically, alphavirus particles are provided having nucleic acid molecules derived from one or more alphaviruses and structural proteins (capsid and/or envelope) from at least two or more alphaviruses. Methods of making, using, and therapeutic preparations containing the chimeric alphavirus particle, are disclosed.
    Type: Grant
    Filed: April 3, 2006
    Date of Patent: August 11, 2009
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: John M. Polo, Silvia Perri, Kent Thudium
  • Patent number: 7572628
    Abstract: The present invention provides compositions and methods for utilizing recombinant alphavirus vectors. Also disclosed are compositions and methods for making and utilizing eukaryotic layered vector initiation systems.
    Type: Grant
    Filed: January 16, 2003
    Date of Patent: August 11, 2009
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Thomas W. Dubensky, Jr., John M. Polo, Carlos E. Ibanez, Stephen M. W. Chang, Douglas J. Jolly, David A. Driver, Barbara A. Belli
  • Patent number: 7531180
    Abstract: Chimeric alphaviruses and alphavirus replicon particles are provided including methods of making and using same. Specifically, alphavirus particles are provided having nucleic acid molecules derived from one or more alphaviruses and structural proteins (capsid and/or envelope) from at least two or more alphaviruses. Methods of making, using, and therapeutic preparations containing the chimeric alphavirus particle, are disclosed.
    Type: Grant
    Filed: April 11, 2002
    Date of Patent: May 12, 2009
    Assignee: Novartis Vaccines and Diagnostics, Inc
    Inventors: John M. Polo, Silvia Perri, Kent Thudium
  • Publication number: 20080292655
    Abstract: Expression cassettes are provided comprising a promoter operably linked to a nucleic acid molecule which, when transcribed in vivo, forms double-stranded RNA that induces the production of interferon. Expression cassettes also are provided comprising a promoter operably linked to a ribozyme or antisense nucleic acid molecule which, when transcribed in vivo, forms a ribozyme or antisense RNA molecule that stimulates an immune response. In addition, expression cassettes are provided comprising a promoter operably linked to a ribozyme or antisense nucleic acid molecule which, when transcribed in vivo, stimulates apoptosis. Finally, gene delivery vectors are provided which contain such expression cassettes, host cells containing the gene delivery vectors, and methods of utilizing the expression cassettes, gene delivery vectors, and host cells.
    Type: Application
    Filed: April 29, 2008
    Publication date: November 27, 2008
    Inventors: Thomas W. Dubensky, JR., John M. Polo, Barbara A. Belli, Silvia Perri, Timothy C. Fong
  • Patent number: 6767699
    Abstract: Methods of production and purification for viruses and virus-derived vectors, including those related to alphaviruses, are disclosed. In one aspect, methods of purification that subject alphavirus replicon particle preparations to one or more steps of chromatographic purification, such as using an ion exchange resin, are provided. Also disclosed are methods of characterizing alphavirus replicon particles and utilizing these materials for vaccines and gene-based therapeutics.
    Type: Grant
    Filed: May 31, 2001
    Date of Patent: July 27, 2004
    Assignee: Chiron Corporation
    Inventors: John M. Polo, Catherine Greer, Thomas W. Dubensky, Jr.
  • Publication number: 20040029278
    Abstract: The present invention provides compositions and methods for utilizing recombinant alphavirus vectors. Also disclosed are compositions and methods for making and utilizing eukaryotic layered vector initiation systems.
    Type: Application
    Filed: May 17, 2002
    Publication date: February 12, 2004
    Applicant: Chiron Corporation
    Inventors: Thomas W. Dubensky, John M. Polo, Carlos E. Ibanez, Stephen M.W. Chang, Douglas J. Jolly, David A. Driver, Barbara A. Belli
  • Publication number: 20030232035
    Abstract: The present invention provides compositions and methods for utilizing recombinant alphavirus vectors. Also disclosed are compositions and methods for making and utilizing eukaryotic layered vector initiation systems.
    Type: Application
    Filed: January 16, 2003
    Publication date: December 18, 2003
    Inventors: Thomas W. Dubensky, John M. Polo, Carlos E. Ibanez, Stephen M.W. Chang, Douglas J. Jolly, David A. Driver, Barbara A. Belli
  • Publication number: 20030232058
    Abstract: Isolated nucleic acid molecules are disclosed, comprising an alphavirus nonstructural protein gene which, when operably incorporated into a recombinant alphavirus particle, eukaryotic layered vector initiation system, or RNA vector replicon, has a reduced level of vector-specific RNA synthesis, as compared to wild-type, and the same or greater level of proteins encoded by RNA transcribed from the viral junction region promoter, as compared to a wild-type recombinant alphavirus particle. Also disclosed are RNA vector replicons, alphavirus vector constructs, and eukaryotic layered vector initiation systems which contain the above-identified nucleic acid molecules.
    Type: Application
    Filed: March 17, 2003
    Publication date: December 18, 2003
    Inventors: Thomas W. Dubensky, John M. Polo, Barbara A. Belli, Sondra Schlesinger, Sergey A. Drvga, Ilya Frolov
  • Publication number: 20030232324
    Abstract: Chimeric alphaviruses and alphavirus replicon particles are provided including methods of making and using same. Specifically, alphavirus particles are provided having nucleic acid molecules derived from one or more alphaviruses and structural proteins (capsid and/or envelope) from at least two or more alphaviruses. Methods of making, using, and therapeutic preparations containing the chimeric alphavirus particle, are disclosed.
    Type: Application
    Filed: December 4, 2002
    Publication date: December 18, 2003
    Applicant: Chiron Corporation
    Inventors: John M. Polo, Silvia Perri, Kent Thudium, Zequn Tang